Institutul Inimii De Urgenta Pentru Boli Cardiovasculare Niculae Stancioiu
- Address
- lock Available on a paid plan
Cardiovascular Diseases at Institutul Inimii De Urgenta Pentru Boli Cardiovasculare Niculae Stancioiu
Research at this cardiology site focuses on major cardiovascular diseases, especially hypertension, established cardiovascular disease, and high cardiovascular risk. The studies are designed to test new treatment options and better prevent serious heart and blood vessel events.
- Prevention of major adverse cardiovascular events in people at elevated risk
- Improving care for patients with hypertension that remains difficult to control
- Evaluating treatments intended to reduce cardiovascular death, heart attack, and stroke
- Studying therapies aimed at lowering risk in primary prevention of atherosclerotic cardiovascular disease
The site is also involved in research on transthyretin amyloidosis with cardiomyopathy, reflecting interest in less common but serious heart conditions and in therapies that may improve long-term outcomes.
Pulmonary Arterial Hypertension Research
This set of trials centers on pulmonary arterial hypertension, a severe condition that affects the blood vessels in the lungs and places strain on the heart. The research is focused on testing new therapies and understanding their longer-term safety and benefit.
- Assessing treatment effectiveness for PAH
- Monitoring long-term safety and tolerability of emerging therapies
- Exploring options to reduce clinical worsening in patients with pulmonary arterial hypertension
- Supporting better disease control for people living with advanced cardiopulmonary disease
These studies show a strong commitment to improving outcomes in a complex pulmonary hypertension population.
Innovative Prevention and Treatment Studies
The clinical trial portfolio at this hospital includes research aimed at both preventing future cardiovascular events and treating already established disease. The work spans newer approaches to lowering risk, protecting the heart, and improving quality of care for patients with chronic heart disease.
- Testing therapies for better prevention of atherosclerotic cardiovascular disease
- Evaluating medicines for patients with cardiomyopathy linked to amyloid disease
- Studying treatment approaches for persistent hypertension and related complications
- Advancing options for patients with both high risk and established cardiovascular disease
Overall, the research emphasizes practical clinical benefits, including safer long-term use, stronger prevention, and more effective management of serious cardiac conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Alnylam Pharmaceuticals Inc.2active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG3trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institutul Inimii De Urgenta Pentru Boli Cardiovasculare Niculae Stancioiu
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-controlled, Event-driven Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, After a Recent Acute Coronary Syndrome | Janssen Cilag International | Phase III | Not Recruiting | Nov 2023 | Jan 2026 |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 2 | Unknown | 2023-09-04 | 2023-09-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.